375 related articles for article (PubMed ID: 11092663)
1. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure.
Nieminen MS; Akkila J; Hasenfuss G; Kleber FX; Lehtonen LA; Mitrovic V; Nyquist O; Remme WJ
J Am Coll Cardiol; 2000 Nov; 36(6):1903-12. PubMed ID: 11092663
[TBL] [Abstract][Full Text] [Related]
2. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Investigators.
Slawsky MT; Colucci WS; Gottlieb SS; Greenberg BH; Haeusslein E; Hare J; Hutchins S; Leier CV; LeJemtel TH; Loh E; Nicklas J; Ogilby D; Singh BN; Smith W
Circulation; 2000 Oct; 102(18):2222-7. PubMed ID: 11056096
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
J Clin Pharmacol; 2002 Jan; 42(1):43-51. PubMed ID: 11808823
[TBL] [Abstract][Full Text] [Related]
4. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
5. [Therapy of acute decompensated heart failure with levosimendan].
Müller K; Peters A; Zeus T; Hennersdorf M; Strauer BE
Med Klin (Munich); 2006 Mar; 101 Suppl 1():119-22. PubMed ID: 16802535
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
Kivikko M; Lehtonen L
Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic effects of levosimendan added to dobutamine in patients with decompensated advanced heart failure refractory to dobutamine alone.
Nanas JN; Papazoglou PP; Terrovitis JV; Kanakakis J; Dalianis A; Tsolakis E; Tsagalou EP; Agrios N; Christodoulou K; Anastasiou-Nana MI
Am J Cardiol; 2004 Nov; 94(10):1329-32. PubMed ID: 15541261
[TBL] [Abstract][Full Text] [Related]
8. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure.
Kivikko M; Antila S; Eha J; Lehtonen L; Pentikäinen PJ
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):465-71. PubMed ID: 12395979
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of levosimendan in patients with low-output heart failure after cardiac surgery.
Labriola C; Siro-Brigiani M; Carrata F; Santangelo E; Amantea B
Int J Clin Pharmacol Ther; 2004 Apr; 42(4):204-11. PubMed ID: 15124978
[TBL] [Abstract][Full Text] [Related]
11. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
12. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines.
Delle Karth G; Buberl A; Geppert A; Neunteufl T; Huelsmann M; Kopp C; Nikfardjam M; Berger R; Heinz G
Acta Anaesthesiol Scand; 2003 Nov; 47(10):1251-6. PubMed ID: 14616323
[TBL] [Abstract][Full Text] [Related]
13. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
14. Levosimendan: a review of its use in the management of acute decompensated heart failure.
Innes CA; Wagstaff AJ
Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
[TBL] [Abstract][Full Text] [Related]
15. Myocardial efficiency during levosimendan infusion in congestive heart failure.
Ukkonen H; Saraste M; Akkila J; Knuuti J; Karanko M; Iida H; Lehikoinen P; Någren K; Lehtonen L; Voipio-Pulkki LM
Clin Pharmacol Ther; 2000 Nov; 68(5):522-31. PubMed ID: 11103755
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.
Follath F; Cleland JG; Just H; Papp JG; Scholz H; Peuhkurinen K; Harjola VP; Mitrovic V; Abdalla M; Sandell EP; Lehtonen L;
Lancet; 2002 Jul; 360(9328):196-202. PubMed ID: 12133653
[TBL] [Abstract][Full Text] [Related]
17. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of levosimendan in pediatric patients evaluated for cardiac surgery.
Turanlahti M; Boldt T; Palkama T; Antila S; Lehtonen L; Pesonen E
Pediatr Crit Care Med; 2004 Sep; 5(5):457-62. PubMed ID: 15329162
[TBL] [Abstract][Full Text] [Related]
19. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
[TBL] [Abstract][Full Text] [Related]
20. Sustained hemodynamic effects of intravenous levosimendan.
Kivikko M; Lehtonen L; Colucci WS
Circulation; 2003 Jan; 107(1):81-6. PubMed ID: 12515747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
